If you have Cigna and your gastroenterologist has prescribed Entyvio for Crohn's disease, the practical question is whether your plan will pay for it and what you need to do to get approved. In most cases the answer is that Cigna does cover Entyvio for Crohn's, but coverage is conditional. The drug sits behind prior authorization, and approval depends on meeting the criteria Cigna spells out in its published coverage policy. This article explains how Cigna manages Entyvio, what its policy typically requires, where the drug falls between your medical and pharmacy benefits, and how to respond if a request is denied. Always confirm the details against your own plan documents, because the standard policy can differ from what your specific employer or plan has negotiated.
How Cigna manages Entyvio coverage
Cigna administers pharmacy benefits in partnership with Express Scripts, and it dispenses specialty biologics through Accredo, its specialty pharmacy for injected and infused medications that need special handling. Entyvio is a specialty biologic, so once approved it is usually filled and shipped through Accredo with clinical support from specialty-trained pharmacists and nurses. Entyvio, the brand name for vedolizumab, is a gut-selective monoclonal antibody that binds the alpha-4-beta-7 integrin to block inflammatory lymphocytes from entering the gastrointestinal tract. It received its initial U.S. approval in 2014 and is now indicated for both moderately to severely active Crohn's disease and ulcerative colitis. How Cigna pays for it depends on which form you receive and which benefit applies.
Medical benefit versus pharmacy benefit
Entyvio for Crohn's is given as an intravenous infusion of 300 mg at weeks 0, 2, and 6, then every 8 weeks, with a subcutaneous maintenance option of 108 mg every 2 weeks after at least two IV doses. This split matters for billing. An infusion given in a clinic or infusion center is typically processed under the medical benefit, while a self-administered subcutaneous injection shipped to your home usually runs through the pharmacy benefit. The benefit that applies affects your cost share, since infusions may count toward a medical deductible while pharmacy fills follow your drug coverage tiers. Cigna maintains separate prior-authorization policies for the intravenous form and the subcutaneous form, so the route your doctor chooses determines which set of rules governs your request.
What Cigna's coverage policy typically requires
Cigna's policy states that prior authorization is required for benefit coverage of Entyvio intravenous. For Crohn's disease, the standard policy approves initial therapy for six months when the patient is at least 18 years old and the medication is prescribed by or in consultation with a gastroenterologist. Notably, Cigna's policy reflects current society guidance. It cites the American College of Gastroenterology and American Gastroenterological Association 2025 guidelines, which recommend upfront use of advanced therapies rather than strict step-up after conventional drugs fail. Even so, many plans layer their own step-therapy requirements on top of the base policy, so you may still need documented trials of corticosteroids, immunomodulators, or a preferred biologic before approval. Read your own plan's formulary to see whether step therapy applies to you.
Documenting medical necessity
A clean prior-authorization request gives the reviewer the clinical record needed to approve on the first pass. The strongest submissions tie your diagnosis to objective evidence and to the criteria in Cigna's policy. Helpful elements to gather include the following.
A confirmed Crohn's diagnosis with disease activity supported by endoscopy, imaging, or biomarkers such as fecal calprotectin or C-reactive protein
A clear treatment history showing which therapies you tried, how long, and why they failed or were stopped
A gastroenterologist's note documenting moderate to severe disease and the rationale for Entyvio
Cigna's renewal criteria reward this documentation. For continued coverage past the initial period, the policy approves up to one year when the patient has been on the drug for at least six months and shows a beneficial clinical response measured by an objective marker such as fecal calprotectin, C-reactive protein, or endoscopy. Tracking these measures from the start makes both the initial request and the renewal easier.
Why Entyvio is often approved for Crohn's
Entyvio is frequently positioned as a preferred biologic because its evidence base in Crohn's is strong and its gut-selective action limits systemic immune suppression. In the GEMINI 2 maintenance trial, 39 percent of patients who responded to induction and continued vedolizumab every 8 weeks were in clinical remission at week 52, compared with 21.6 percent on placebo. That durable maintenance benefit, combined with guideline endorsement, is part of why payers like Cigna tend to cover it when the documentation supports moderate to severe disease. A preferred status does not remove the prior-authorization step, but it can mean fewer alternatives you must fail first compared with a newer or non-preferred agent.
If your request is denied
A denial is not the end of the process. Cigna's coverage policies are guidance documents, and a customer's specific benefit plan document always supersedes them in the event of a conflict. Start by reading the denial letter to identify the exact criterion you did not meet, whether that is missing documentation, an unmet step-therapy requirement, or a benefit exclusion. Your gastroenterologist can submit an appeal with a letter of medical necessity that addresses the cited reason directly, attaches the supporting records, and references the relevant policy criteria. If the internal appeal is unsuccessful, you can usually request an external review by an independent third party. Cigna does cover Entyvio for many Crohn's patients, and a denial often reflects a gap in the paperwork rather than a final judgment on whether the drug is appropriate for you.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.